Compare BIO-TECHNE Corp (TECH) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Global X Uranium ETF — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.36B), while Global X Uranium ETF trades at $38.96 (market cap $5.48B). The key difference: BIO-TECHNE Corp is far larger — about 2.1× Global X Uranium ETF's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Global X Uranium ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Global X Uranium ETF for 62 Days on average.
| TECH | URA | |
|---|---|---|
Market Cap | $11.36B | $5.48B |
Volume | 5,390,331 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $72.61 | $61.81 |
52-Week Low | $43.31 | $37.52 |
Typical Hold Time | 63 Days | 62 Days |
Enterprise Value | $11.39B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
URA (Global X Uranium ETF) is trading at $39.93, down 4.47% over the past 24 hours amid bearish technical signals. The ETF faces selling pressure with 16 technical indicators signaling sell versus only 1 buy signal. Recent news highlights nuclear energy's growth potential driven by AI power demand and government support, but uranium ETFs have experienced significant volatility with a 30% correction in August 2026 despite positive sector fundamentals.
The long-term outlook remains positive given nuclear energy's role in meeting AI and electrification demands, with the U.S. targeting 300GW of new nuclear capacity by 2050. Key risks include commodity price volatility and single-stock concentration, while opportunities exist through diversified exposure to the nuclear supply chain. Current technical weakness suggests potential for further consolidation before resuming upward trend.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
